Research on Effects of Comorbidities Disease on Anticoagulation and Bleeding Disorders Risk in Patients with Overdosage of Vitamin K Antagonist Anticoagulant
Objectives: Research on effects of comorbidities disease on anticoagulation overdose in patients receiving anticoagulant therapy with vitamin K antagonists anticoagulant (VKAs) drugs at HaiPhong-VinhBao International General Hospital. Methods: Description and Prospective study. Research on 79 patients receiving anticoagulant therapy with VKAs who have an INR testing index of more than anticoagulation dose with VKAs and check INR every 4 weeks. Results: The average research age is 65.65 ± 12.17 years [33: 85], most of the elderly group. The Male group is lower than the female group (p > 0.05). Patients with hemorrhage signs account for 22.8%. The INR testing index has an average value is 5.88 ± 3.0 [3.02 - 23.95]; The group of INR > 5 level is a higher risk of bleeding than the group of INR ≤ 5 levels, there is statistical difference (p < 0.001). Patients using anti-vitamin K drugs on the background of patients with many complicated conditions are easily at risk of bleeding, especially in patients with renal falure and musculoskeletal disease are the cause of the increased risk of bleeding with the rate of the difference is OR = 3.64 (CI: 1.17 - 11.32, with p < 0.05) and OR = 3.52 (CI: 1.19 - 10.47, with p < 0.05) of statistical significance. Conclusion: All most patients with anticoagulation overdose are in the elderly group. The group with INR > 5 levels has a higher risk of bleeding than the group with INR ≤ 5 levels, it’s the statistical significance (p < 0.001). The comorbidities Diseases such as hypertension, ischemic heart disease, coronary stents, old myocardial infarction, Graves, and gastritis all have the risk of increasing the risk of bleeding when taking anticoagulants but not yet statistically significant (have OR > 1 but p > 0.05); Patients used VKAs drugs on the background of kidney failure or arthritis pathology are the cause of the increased risk of bleeding, it’s statistical significance (p < 0.05).
References
[1]
Vos, M., Esposito, G., Edirisinghe, J.N., et al. (2012) Vitamin K2 Is a Mitochondrial Electron Carrier That Rescues Pink1 Deficiency. Science, 336, 1306-1310. https://doi.org/10.1126/science.1218632
[2]
Watson, H.G., Baglin, T., Laidlaw, S.L., Makris, M. and Preston, F.E. (2001) A Comparison of the Efficacy and Rate of Response to Oral and Intravenous Vitamin K in Reversal of Over-Anticoagulation with Warfarin. British Journal of Hematology, 115, 145-149. https://doi.org/10.1046/j.1365-2141.2001.03070.x
[3]
Palareti, G., Leali, N., Cocheri, S., et al. (1996) Bleeding Complications of Oral Anticoagulant Treatment: An Inception-Cohort, Prospective Collaborative Study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. The Lancet, 348, 423-428. https://doi.org/10.1016/S0140-6736(96)01109-9
[4]
Wysowski, D.K., Nourjah, P. and Swartz, L. (2007) Bleeding Complications with Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action. Archives of Internal Medicine, 167, 1414-1419. https://doi.org/10.1001/archinte.167.13.1414
[5]
Eichinger, S. (2016) Reversing Vitamin K Antagonists: Making the Old New Again. American Society of Hematology, 2016, 605-611. https://doi.org/10.1182/asheducation-2016.1.605
[6]
Steffel, J., Collins, R., Antz, M., et al. (2021) 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 23, 1612-1676. https://doi.org/10.1093/europace/euab065
[7]
Shah, M., Tsadok, M.A., Jackevicius, C.A., et al. (2014) Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis. Circulation, 129, 1196-1203. https://doi.org/10.1161/CIRCULATIONAHA.113.004777
[8]
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al (2009) Dabigatran versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine, 361, 1139-1151. https://doi.org/10.1056/NEJMoa0905561
[9]
Koutrouvelis, A., Abouleish, A., Indrikovs, A., et al. (2010) Case Scenario: Emerengency Reserval of Oral Anticoagulation. Anesthesiology, 113, 1192-1197. https://doi.org/10.1097/ALN.0b013e3181f7a7a3
[10]
Gunther, K.E., Conway, G., Leibach, L. and Crowther, M.A. (2004) Low-Dose Oral Vitamin K Is Safe and Effective for Outpatient Management of Patients with an INR > 10. Thrombosis Research, 113, 205-209. https://doi.org/10.1016/j.thromres.2004.03.004
[11]
Bhatia, H.S., Hsu, J.C. and Kim, R.J. (2018) Atrial Fibrillation and Chronic Kydney Disease: A Review of Options for Therapeutic Anticoaglulation to Reduce Thromboembolism Risk. Clinical Cardiology, 41, 1395-1402. https://doi.org/10.1002/clc.23085
[12]
O’Sullivan, S.M., Galvin, K., Heneghan, C., et al. (2018) Does Daily Consumption of Vitamin K1 from Cruciferous Vegetables Reach the Circulation and the Knee Joint? Proceedings of the Nutrition Society, 77, E68. https://doi.org/10.1017/S0029665118000721
[13]
Kurosu, M. and Began, E. (2010) Vitamin K2 in Electron Transport System: Are Enzymes Involved in Vitamin K2 Biosynthesis Promising Drug Targets? Molecules, 15, 1531-1553. https://doi.org/10.3390/molecules15031531
[14]
Davis, E., Darais, D., Fuji, K., Nekola, P. and Bashir, K. (2020) Prescribing and Safety of Direct-Ating Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. Pharmacy, 8, Article No. 37. https://doi.org/10.3390/pharmacy8010037
[15]
Boer, C.G., Szilagyi, I., Nguyen, N.L., et al. (2021) Vitamin K Antagonist Anticoagulant Usage Is Associated with Increased Incidence and Progression of Osteoarthritis. Annals of the Rheumatic Diseases, 80, 598-604. https://doi.org/10.1136/annrheumdis-2020-219483
[16]
Bellone, F., Cinquegrani, M., Nicotera, R., et al. (2022) Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health. International Journal of Molecular Sciences, 23, Article No. 5282. https://doi.org/10.3390/ijms23095282
